---
title: "Mazdutide"
canonical_url: https://peptidelibrary.app/library/mazdutide
description: "Dual agonist at the GLP-1 and glucagon receptors, developed principally in China and approved there by the National Medical Products Administration in 2025 for weight management and type 2 diabetes. It combines incretin-driven appetite reduction with glucagon-driven increases in hepatic energy expenditure. It has not been reviewed or approved by the FDA and is not available as a prescription medicine in the United States."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Mazdutide

Mazdutide (also called IBI362 or LY3305677) is a glucagon dual agonist (NMPA-approved; not FDA) in the GLP-1 Agonist class. Mazdutide is a dual agonist at the GLP-1 and glucagon receptors derived from the oxyntomodulin scaffold and acylated for weekly administration.

Dual agonist at the GLP-1 and glucagon receptors, developed principally in China and approved there by the National Medical Products Administration in 2025 for weight management and type 2 diabetes. It combines incretin-driven appetite reduction with glucagon-driven increases in hepatic energy expenditure. It has not been reviewed or approved by the FDA and is not available as a prescription medicine in the United States.

Also known as: IBI362, LY3305677, Xinermei (China).

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: GLP-1/glucagon dual agonist (NMPA-approved; not FDA)
- Mechanism class: GLP-1 Agonist
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

Mazdutide is a dual agonist at the GLP-1 and glucagon receptors derived from the oxyntomodulin scaffold and acylated for weekly administration. GLP-1 receptor activation reduces energy intake and enhances glucose-dependent insulin secretion; glucagon receptor activation increases resting energy expenditure and hepatic fat oxidation. It has been developed principally in China, where phase 3 programmes supported regulatory approval by the National Medical Products Administration. It has not been approved by the FDA, and the balance between the two receptor activities is what determines its glycaemic profile relative to pure GLP-1 agonists.

Targets: GLP-1 receptor, Glucagon receptor.

Origin: Synthetic oxyntomodulin analog (Innovent/Lilly lineage).

## Properties

- Molecular formula: C207H317N45O65
- Molecular weight: 4,476 g/mol
- CAS number: 2259884-03-0
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 2
- Controlled human trials: 2
- Preclinical sources: 0
- Latest source: 2026

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025. 2025. Controlled human trial. Population: Chinese adults with obesity, or overweight with a weight-related condition (n=610) [Source](https://pubmed.ncbi.nlm.nih.gov/40421736/)
2. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026. 2026. Controlled human trial. Population: Chinese adults with obesity (461 analysed). Mean body-weight change at week 60: -16.7% vs -1.5% with placebo [Source](https://pubmed.ncbi.nlm.nih.gov/42251595/)

## Safety

Side effects: GI AEs; Increased heart rate possible.

Risks: Not FDA-approved; US research-chem listings are not Xinermei.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Mazdutide is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Mazdutide?

Dual agonist at the GLP-1 and glucagon receptors, developed principally in China and approved there by the National Medical Products Administration in 2025 for weight management and type 2 diabetes. It combines incretin-driven appetite reduction with glucagon-driven increases in hepatic energy expenditure. It has not been reviewed or approved by the FDA and is not available as a prescription medicine in the United States.

### How does Mazdutide work?

Mazdutide is a dual agonist at the GLP-1 and glucagon receptors derived from the oxyntomodulin scaffold and acylated for weekly administration. GLP-1 receptor activation reduces energy intake and enhances glucose-dependent insulin secretion; glucagon receptor activation increases resting energy expenditure and hepatic fat oxidation.

### Is Mazdutide FDA approved?

No. Mazdutide is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What peptides are similar to Mazdutide?

Compounds most often compared with Mazdutide include Retatrutide, Survodutide, Pemvidutide and Cotadutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials — Diabetes Obes Metab, 2026](https://pubmed.ncbi.nlm.nih.gov/41804840/)
- [Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials — Am J Ther, 2024](https://pubmed.ncbi.nlm.nih.gov/39292847/)
- [Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes — Nature, 2026](https://pubmed.ncbi.nlm.nih.gov/41407860/)
- [Mazdutide versus placebo in Chinese adults with type 2 diabetes — Nature, 2026](https://pubmed.ncbi.nlm.nih.gov/41407859/)
- [Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight — N Engl J Med, 2025](https://pubmed.ncbi.nlm.nih.gov/40421736/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
